A prostate nodule is a localized area of the prostate that feels or appears different from the surrounding gland. It may be discovered as a firm, hard or irregular area during a digital rectal examination (DRE), or a focal abnormality may later be identified on ultrasound or MRI. A nodule can be associated with prostate cancer, but a prostate nodule is not itself a cancer diagnosis. Benign prostate enlargement, inflammation, fibrosis, calcification and other non-cancer conditions can also produce focal abnormalities.
When a clinician feels a suspicious prostate nodule, the finding changes the estimated probability of prostate cancer rather than proving malignancy. Evaluation commonly combines the character of the DRE finding with PSA testing, prostate volume and PSA density, clinical risk factors and prostate MRI. If the combined evidence remains suspicious, targeted prostate biopsy is used to determine what the tissue actually contains.
01What Is a Prostate Nodule and What Can a DRE Actually Feel?
A nodule describes a focal physical abnormality—not its cause
During a digital rectal examination, a clinician inserts a lubricated gloved finger into the rectum and palpates the posterior surface of the prostate through the rectal wall.
The examination can provide information about:
- prostate size;
- symmetry;
- surface contour;
- consistency;
- tenderness;
- discrete nodules;
- diffuse hardness or induration;
- and fixation or irregularity suggestive of more locally advanced disease.
A prostate nodule generally refers to a localized area that feels distinctly different from the surrounding prostate tissue.
What does a suspicious prostate nodule feel like?
No tactile feature can diagnose cancer by itself, but findings that can increase concern include:
- a distinctly hard focus;
- a firm irregular nodule;
- new asymmetry accompanied by abnormal consistency;
- loss of the normally smooth prostate surface;
- diffuse stony induration;
- or apparent fixation to surrounding tissue.
A subtle difference in texture is much less specific than a clearly hard or irregular abnormality.
What does a normal prostate usually feel like?
A normal adult prostate is generally:
- smooth;
- rubbery or firm rather than rock-hard;
- relatively symmetrical;
- and without a distinctly irregular focal mass.
Age and benign enlargement can make the gland larger without necessarily creating a malignant-feeling nodule.
Can DRE examine the entire prostate?
No.
This is one of the most important limitations of the examination.
The rectum lies behind the prostate, so the examining finger has best access to the posterior and posterolateral surface.
Anterior tumors, deep transition-zone lesions and some apical or very small tumors may not be palpable.
A normal DRE therefore cannot exclude prostate cancer.
How often can an abnormal DRE identify prostate cancer?
Current European Association of Urology guidance reports that approximately 18% of prostate cancers have historically been detected because of a suspicious DRE irrespective of PSA level.
Among men with PSA at or below 4 ng/mL, a suspicious DRE has had reported positive predictive values of roughly 5% to 30%.
That wide range is important.
It means:
- a palpable abnormality can identify cancers that PSA alone might not flag;
- but most suspicious examination findings in some populations still do not prove cancer.
What if both PSA and DRE are abnormal?
Suspicion rises when independent findings point in the same direction.
EAU cites the ERSPC screening experience in which an abnormal DRE combined with elevated PSA more than doubled the chance of a positive biopsy compared with elevated PSA without an abnormal DRE.
The important principle is not to memorize one percentage.
It is that:
PSA and DRE provide independent information.
For a direct comparison of the two tests, see PSA vs Digital Rectal Examination.
Can DRE estimate prostate size accurately?
Only approximately.
DRE can distinguish a clearly enlarged gland from a small one, but it is less reliable for precise volume calculation.
MRI or ultrasound provides more reproducible measurements when prostate volume is needed to calculate PSA density.
A DRE finding is a physical sign, not a pathology result. Its greatest value comes from adding information to the rest of the cancer-risk assessment—especially when a clearly hard, irregular or fixed area is present despite a PSA value that would otherwise appear less concerning.
02What Can Cause a Prostate Nodule Besides Prostate Cancer?
Prostate cancer is important—but it is not the only cause
A hard prostate nodule warrants evaluation because prostate adenocarcinoma can create a focal area of firm or irregular tissue.
But the prostate can develop focal abnormalities from several benign or inflammatory processes.
The differential diagnosis includes:
- prostate adenocarcinoma;
- benign prostatic hyperplasia;
- chronic prostatitis or focal inflammation;
- granulomatous prostatitis;
- fibrosis or scarring;
- calcification and prostatic calculi;
- post-procedure changes;
- hemorrhage;
- cysts;
- abscess in the appropriate clinical setting;
- and less common benign or malignant prostate conditions.
How can prostate cancer create a nodule?
Adenocarcinoma can replace normal glandular tissue with:
- densely packed malignant glands;
- fibrotic stromal reaction;
- infiltrative tumor;
- and loss of normal tissue elasticity.
This can create a firm or hard area palpable through the rectum.
More extensive disease can make the gland:
- irregular;
- asymmetrical;
- diffusely hard;
- or apparently fixed.
Can benign prostate enlargement form nodules?
Yes.
Benign prostatic hyperplasia develops through nodular growth, particularly in the transition zone surrounding the urethra.
These benign nodules can be:
- glandular;
- stromal;
- or mixed.
Many produce smooth symmetrical enlargement rather than a classic hard posterior nodule, but individual nodules can create asymmetry or focal abnormalities on imaging.
For the distinction between benign growth, prostate enlargement and obstruction, see the BPH guide.
Can prostatitis create a firm or nodular prostate?
Yes.
Inflammation can alter prostate texture and can also produce focal abnormalities on MRI.
Chronic inflammatory disease may cause:
- edema;
- fibrosis;
- focal induration;
- and tissue changes that overlap with cancer imaging.
Granulomatous prostatitis is a particularly important mimic because it can produce:
- an abnormal DRE;
- elevated PSA;
- strong diffusion restriction;
- and a highly suspicious MRI appearance.
The broader distinction between infection, inflammation and chronic pelvic pain is explained in the Prostatitis and Prostate Pain hub.
Can calcifications feel like a nodule?
Prostatic calcifications and calculi can occasionally contribute to firm focal texture, especially when calcification is substantial.
Most small calcifications are incidental imaging findings rather than a clinically important palpable mass.
They should not be interpreted as cancer merely because they are hard.
See Prostate Calcifications and Prostatic Stones for how calculi form and when they matter.
What about fibrosis or scarring?
Previous inflammation, treatment, biopsy or other tissue injury can leave fibrotic tissue.
Fibrosis can be firm and can alter both palpation and MRI appearance.
The clinical history becomes important because scar tissue after known treatment carries a different context from a new unexplained nodule in a previously uninvestigated prostate.
Can an abscess feel abnormal?
An acute prostate abscess usually presents in a very different clinical setting.
Possible features include:
- fever;
- systemic illness;
- pelvic or perineal pain;
- urinary symptoms;
- retention;
- and persistent bacterial prostatitis despite treatment.
The prostate can be tender and occasionally fluctuant rather than simply forming an asymptomatic hard nodule.
Importantly, aggressive prostate massage should not be performed in acute bacterial prostatitis.
The serious infectious condition is covered separately in Prostate Abscess.
Does pain make a nodule more or less likely to be cancer?
Pain is not a reliable discriminator.
Localized prostate cancer is commonly asymptomatic.
Marked tenderness, fever and acute urinary symptoms make bacterial or inflammatory disease more clinically plausible, but cancer and benign disease can coexist.
Pain should therefore be interpreted as another clinical attribute rather than as a rule-out test for malignancy.
Do not assume “hard = cancer” or “tender = infection.” These features change the differential diagnosis, but none has enough specificity to identify the underlying pathology by touch alone.
03How Is a Suspicious Prostate Nodule Evaluated for Cancer?
The first step is to establish the whole risk context
A suspicious DRE does not exist in isolation.
Evaluation commonly considers:
- age;
- current PSA;
- previous PSA results;
- prostate size;
- family history;
- known genetic variants;
- urinary symptoms;
- infection or inflammatory symptoms;
- previous prostate biopsy;
- previous prostate procedures;
- and medications that alter PSA.
Does a suspicious nodule matter if PSA is normal?
Yes.
PSA is highly useful but not cancer-specific and not perfectly sensitive.
A small proportion of clinically important cancers occur with PSA values that would not otherwise trigger evaluation.
EAU guidance therefore states that an abnormal DRE is an indication for prostate MRI, or in selected situations direct biopsy when examination suggests clearly extracapsular or locally advanced disease.
Does an elevated PSA prove that the nodule is cancer?
No.
PSA can rise from:
- prostate cancer;
- benign prostate enlargement;
- prostatitis;
- urinary retention;
- and selected prostate or urinary procedures.
This is why a man with both a nodule and elevated PSA moves into a higher-suspicion evaluation pathway rather than being diagnosed from the blood test.
For benign explanations of PSA elevation, see High PSA Without Prostate Cancer.
What does prostate MRI add?
MRI can answer questions DRE cannot:
- Is there a focal lesion corresponding to the palpable area?
- Is the abnormality in the peripheral or transition zone?
- How large is it?
- Does it restrict diffusion?
- Is its morphology suspicious?
- Does it contact or extend beyond the capsule?
- Is another lesion present elsewhere in the prostate?
- What is the prostate volume?
These features are described in greater detail in What Is a Prostate MRI? and Multiparametric Prostate MRI.
What role does PI-RADS play?
If MRI identifies a suspicious lesion, the radiologist commonly assigns a PI-RADS category from 1 to 5.
PI-RADS indicates the imaging likelihood of clinically significant prostate cancer:
- 1 = very low suspicion;
- 2 = low;
- 3 = equivocal;
- 4 = high;
- 5 = very high.
The category does not tell whether the palpable nodule is definitely malignant.
What if MRI finds nothing where the clinician felt a nodule?
This is called diagnostic discordance.
Possible explanations include:
- the palpable finding was benign;
- the abnormality was too subtle for MRI;
- the finding reflected fibrosis or calcification;
- the MRI was technically limited;
- or a clinically significant cancer was MRI-invisible.
A negative MRI therefore reduces but does not eliminate cancer risk.
How does PSA density help?
PSA density combines the blood PSA result with prostate volume:
PSA density = PSA ÷ prostate volume.
A higher PSA density generally increases the probability of clinically significant cancer.
It is particularly valuable when:
- MRI is negative;
- the MRI lesion is PI-RADS 3;
- or PSA appears disproportionately high for the measured prostate size.
When does biopsy become appropriate?
Biopsy is considered when the combined evidence leaves enough concern for clinically significant cancer.
Examples include:
- a suspicious DRE plus PI-RADS 4 or 5 lesion;
- a firm nodule with concerning PSA density;
- persistent clinical suspicion despite negative MRI;
- or a suspicious examination in a man with strong inherited risk.
Current prostate-diagnostic pathways increasingly use MRI-targeted biopsy when MRI identifies a lesion.
Why is biopsy still necessary?
Only tissue can usually determine:
- whether malignant glands are present;
- whether the lesion is benign BPH or inflammation;
- Gleason patterns;
- ISUP Grade Group;
- percentage pattern 4;
- cribriform architecture;
- and other histological features.
The complete process is described in Prostate Cancer Diagnosis: PSA, DRE, MRI, Biopsy and Pathology.
What if the clinician suspects disease beyond the prostate?
A diffusely hard, fixed or markedly irregular prostate may raise concern for locally advanced cancer rather than a small isolated nodule.
EAU guidance notes that an abnormal DRE strongly predicts more advanced clinical stage in some cohorts and can justify direct biopsy or staging evaluation when obvious extracapsular disease is suspected.
This is different from finding a small incidental focal nodule in an otherwise smooth gland.
The diagnostic endpoint is not “abnormal prostate.” The endpoint is determining whether the abnormality represents cancer, and if cancer is present, establishing its Grade Group, extent and stage so that treatment decisions are based on disease biology rather than palpation alone.
04What Do Different Combinations of a Prostate Nodule, PSA and MRI Mean?
Nodule + normal PSA
A PSA value within a commonly used reference range does not erase a suspicious examination finding.
The practical next step may include:
- reviewing previous PSA results;
- considering age and family history;
- obtaining prostate MRI;
- and deciding whether biopsy remains justified.
The probability of cancer may be lower than when PSA is markedly elevated, but it is not zero.
Nodule + elevated PSA
This combination increases suspicion because two independent findings are abnormal.
However, it still does not prove malignancy.
A man can simultaneously have:
- BPH causing much of the PSA elevation;
- an inflammatory prostate abnormality;
- and no cancer.
MRI and PSA density help separate these possibilities before biopsy.
Nodule + PI-RADS 4 or 5 lesion in the same location
When the palpable abnormality corresponds to a highly suspicious MRI lesion, the evidence becomes more concordant.
The next step is usually tissue sampling because:
- DRE identifies the physical abnormality;
- MRI identifies suspicious tissue behavior;
- and biopsy determines histology.
A PI-RADS 4 or 5 score still does not tell whether the lesion is:
- Grade Group 1;
- Grade Group 2;
- Grade Group 5;
- or benign.
Nodule + negative MRI
This is a more nuanced situation.
Possible explanations include:
- a benign palpable abnormality;
- fibrosis or calcification;
- a very small tumor;
- an MRI-invisible tumor;
- or technically limited imaging.
The decision to biopsy may then depend heavily on:
- PSA density;
- strength of the DRE abnormality;
- family history;
- genetic risk;
- PSA trajectory;
- and MRI quality.
Nodule + symptoms of acute infection
A man with:
- fever;
- chills;
- dysuria;
- pelvic pain;
- marked prostate tenderness;
- or systemic illness
requires evaluation for bacterial prostatitis or another urinary infection.
Acute bacterial prostatitis changes the immediate priority because infection can cause:
- bacteremia;
- sepsis;
- urinary retention;
- and prostate abscess.
Prostate massage should not be performed in suspected acute bacterial prostatitis.
See Acute Bacterial Prostatitis for that presentation.
Nodule + strong family history or BRCA2
Inherited risk raises the pre-test probability before the nodule is even considered.
A suspicious examination in a man with:
- a father or brother diagnosed young;
- multiple affected first-degree relatives;
- or a pathogenic BRCA2 variant
therefore deserves particularly careful risk assessment.
See Family History and Hereditary Prostate Cancer and BRCA1, BRCA2 and Prostate Cancer.
Nodule + previous negative biopsy
A previous negative biopsy reduces uncertainty only for the tissue that was actually sampled.
Persistent concern may justify:
- review of the previous pathology;
- repeat PSA and PSA density;
- high-quality MRI;
- targeting of a persistent lesion;
- or repeat biopsy when the residual risk remains clinically important.
What does a negative biopsy mean?
It means no cancer was identified in the submitted cores.
It does not necessarily mean:
- the palpable abnormality did not exist;
- the MRI lesion was imaginary;
- or that every part of the prostate was sampled.
If the DRE, MRI and PSA remain discordantly concerning, follow-up can still be necessary.
Does every prostate nodule need immediate biopsy?
No universal rule applies to every nodule.
The decision depends on:
- how suspicious the examination feels;
- PSA and PSA density;
- MRI findings;
- family and genetic risk;
- age;
- life expectancy;
- previous biopsy history;
- and whether the result would change clinical management.
A clearly malignant-feeling or fixed prostate is very different from a mild asymmetry with reassuring PSA density and MRI.
What if cancer is eventually diagnosed?
Once biopsy confirms prostate adenocarcinoma, the word “nodule” is no longer the central clinical issue.
The important attributes become:
- Gleason score;
- ISUP Grade Group;
- PSA;
- tumor extent;
- clinical stage;
- imaging evidence of spread;
- and the patient’s overall health and treatment priorities.
These are organized in the Prostate Cancer hub.
Seek prompt medical evaluation rather than routine follow-up when an abnormal prostate finding occurs together with severe systemic illness, inability to urinate, high fever, progressive neurologic symptoms, new severe bone pain or other signs suggesting complicated infection, urinary obstruction or advanced disease.
→Prostate Nodule vs Prostate Lesion vs Prostate Cancer
| Finding | How it is detected | What it describes | Can it be benign? | What usually resolves the uncertainty? |
|---|---|---|---|---|
| Prostate nodule | DRE, sometimes correlated with imaging | A localized area that feels different from surrounding prostate tissue. | Yes | Risk assessment, MRI and biopsy when clinically indicated. |
| Prostate induration | DRE | Abnormally firm or hard prostate tissue that may be focal or diffuse. | Yes | Clinical history, PSA, imaging and sometimes biopsy. |
| Prostate lesion | MRI, ultrasound or other imaging | A focal imaging abnormality. | Yes | PI-RADS/risk assessment and pathology when necessary. |
| PI-RADS 4 lesion | Prostate MRI | High imaging suspicion for clinically significant cancer. | Yes | Targeted biopsy in most diagnostic settings. |
| PI-RADS 5 lesion | Prostate MRI | Very high imaging suspicion. | Yes, although less commonly | Biopsy pathology in most men. |
| Prostate calcification | Ultrasound, CT or other imaging | Mineral deposited within prostate tissue or ducts. | Usually nonmalignant | Clinical context; usually no cancer workup solely because calcification exists. |
| BPH nodule | Imaging, pathology, sometimes examination | Benign nodular growth, usually centered in the transition zone. | By definition benign | Typical imaging appearance or pathology if uncertainty remains. |
| Prostate adenocarcinoma | Usually prostate biopsy pathology | Malignant glandular prostate tumor. | No | Histopathology establishes the diagnosis. |
?Common Questions About Prostate Nodules
| Question | Practical answer |
|---|---|
| What is a prostate nodule? | A localized part of the prostate that feels or appears different from the surrounding gland. |
| Does a prostate nodule mean cancer? | No. Cancer is one important cause, but BPH, inflammation, fibrosis, calcification and other benign processes can also produce focal abnormalities. |
| Can a doctor feel prostate cancer? | Some cancers produce a hard, irregular or nodular DRE finding, but many cancers—especially small or anterior tumors—cannot be felt. |
| What does a hard prostate nodule mean? | It increases concern for malignancy but does not prove cancer. |
| Can BPH cause a prostate nodule? | Yes. BPH is a nodular benign growth process, particularly in the transition zone. |
| Can prostatitis cause a nodule? | Inflammation and subsequent fibrosis can produce focal firmness or MRI abnormalities that mimic cancer. |
| Can granulomatous prostatitis look like cancer? | Yes. It can mimic prostate cancer on DRE, PSA testing and MRI and may require pathology for distinction. |
| Can calcifications cause a hard prostate? | Substantial calcification can contribute to focal firmness, although most small prostate calcifications are incidental imaging findings. |
| Can a prostate nodule exist with normal PSA? | Yes. PSA and DRE provide different information, and a suspicious DRE can justify further evaluation even when PSA is not markedly elevated. |
| Can prostate cancer occur with normal PSA? | Yes. A low or apparently normal PSA does not completely exclude prostate cancer. |
| Can PSA be high with a benign prostate nodule? | Yes. BPH, prostatitis and other benign prostate conditions can elevate PSA. |
| What happens after a prostate nodule is found? | The usual next steps involve PSA review, clinical risk assessment and prostate MRI, followed by biopsy if the combined findings remain suspicious. |
| Should a prostate nodule get an MRI? | A suspicious DRE is an indication for MRI in current EAU prostate-cancer diagnostic guidance. |
| What if MRI shows PI-RADS 4 in the same location? | The findings are concordantly suspicious, and MRI-targeted biopsy is generally considered. |
| What if MRI shows PI-RADS 5? | The probability of clinically significant cancer is high, but biopsy pathology is still normally needed for confirmation and grading. |
| What if MRI is negative? | Cancer risk falls, but a strongly abnormal DRE, high PSA density, inherited risk or continuing PSA concern may still justify biopsy or close follow-up. |
| Can MRI show something DRE cannot feel? | Yes. MRI can identify anterior, small and deep lesions outside the easiest palpation field. |
| Can DRE find something MRI misses? | Yes. A palpable abnormality can occasionally remain concerning despite negative MRI, particularly if imaging is technically limited or the tumor is MRI-invisible. |
| Does a prostate nodule tell the cancer grade? | No. Grade Group requires microscopic pathology. |
| Does a prostate nodule tell the stage? | No. A nodule may contribute to clinical examination findings, but formal staging uses the full examination, pathology and appropriate imaging. |
| Is asymmetry alone prostate cancer? | No. Mild asymmetry is nonspecific. Abnormal firmness, nodularity and other risk findings determine how concerning the examination is. |
| Can a previous biopsy create firmness? | Previous inflammation, hemorrhage and scarring can alter prostate texture and imaging appearance. |
| Can a prostate nodule disappear? | An inflammatory abnormality can change as inflammation resolves, but a previously suspicious finding should not simply be assumed harmless without appropriate clinical follow-up. |
| Does a painful nodule mean prostatitis instead of cancer? | No. Tenderness makes inflammation more plausible but does not by itself exclude malignancy. |
| Is biopsy always required? | No. The decision depends on DRE severity, PSA, PSA density, MRI, family/genetic risk, prior biopsy history, age and whether diagnosis would alter management. |
| What actually confirms prostate cancer? | Histopathological examination of biopsy tissue in most diagnostic settings. |
ΣKey Clinical Takeaways
- A prostate nodule is a localized abnormal area of prostate tissue.
- It may be discovered by DRE or correlated with a focal imaging abnormality.
- A prostate nodule is not synonymous with prostate cancer.
- DRE mainly evaluates the posterior and posterolateral surface of the prostate.
- Anterior and small tumors may not be palpable.
- A normal DRE does not exclude prostate cancer.
- A suspicious DRE can identify clinically important disease even when PSA is not markedly elevated.
- Current EAU evidence states that approximately 18% of prostate cancers have historically been detected because of suspicious DRE irrespective of PSA.
- In men with PSA at or below 4 ng/mL, reported positive predictive value for a suspicious DRE has ranged roughly from 5% to 30%.
- A clearly hard, irregular or fixed prostate is generally more concerning than mild asymmetry alone.
- Benign prostate hyperplasia is a nodular benign growth process.
- Chronic inflammation and fibrosis can create focal firmness.
- Granulomatous prostatitis can closely mimic prostate cancer.
- Calcification can occasionally contribute to hard focal texture but is not itself a cancer diagnosis.
- Acute bacterial prostatitis generally presents with pain, urinary symptoms and systemic illness rather than an isolated asymptomatic hard nodule.
- PSA is prostate-specific but not cancer-specific.
- A normal PSA cannot completely exclude cancer.
- An elevated PSA cannot prove that a nodule is malignant.
- Prostate MRI maps focal abnormalities that DRE cannot fully characterize.
- PI-RADS describes MRI suspicion rather than histological diagnosis.
- PSA density helps interpret MRI and DRE findings in the context of prostate size.
- A nodule corresponding to PI-RADS 4 or 5 tissue usually warrants strong consideration of biopsy.
- A negative MRI lowers risk but cannot completely dismiss a strongly suspicious DRE.
- Inherited risk such as BRCA2 can raise the significance of an abnormal examination.
- A previous negative biopsy does not guarantee that every part of the prostate is cancer-free.
- Biopsy pathology usually determines whether the abnormality is cancer, BPH, inflammation or another process.
- Pathology also determines Gleason score and ISUP Grade Group when cancer is present.
- Grade Group and cancer stage cannot be determined from palpation alone.
- Once cancer is confirmed, treatment decisions depend on PSA, Grade Group, stage, tumor extent, overall health and patient preferences rather than on the original word “nodule.”
Clinical bottom line: a prostate nodule is a finding, not a final diagnosis. A hard or irregular area on DRE deserves attention because prostate cancer can present this way, including in some men without a markedly elevated PSA. But benign hyperplasia, inflammation, fibrosis and calcification can produce similar abnormalities. The safest interpretation comes from combining the physical examination with PSA, prostate volume, PSA density, MRI and individual cancer risk. When those findings remain sufficiently suspicious, biopsy pathology determines what the nodule actually represents.
Medical disclaimer: This article provides general medical education and cannot determine whether a specific prostate nodule is benign or malignant. Evaluation depends on the exact DRE finding, PSA history, prostate volume, MRI results, family history, genetics, infection symptoms, previous biopsies, age and overall health. A suspicious prostate examination should be interpreted by a qualified clinician rather than self-diagnosed from symptoms or laboratory values alone.
For the full process from abnormal examination or PSA through tissue diagnosis, see How Prostate Cancer Is Diagnosed. If imaging is the next step, continue with What Is a Prostate MRI?, Multiparametric Prostate MRI and PI-RADS Scoring. For the blood-test side of the evaluation, see PSA Testing, PSA Density and PSA vs DRE. If family or inherited risk is part of the picture, see Prostate Cancer Risk Factors, Family History and Hereditary Prostate Cancer and BRCA1, BRCA2 and Prostate Cancer. For the broader disease pathway, return to the Prostate Cancer hub. The next guide explains what doctors mean by a prostate lesion, including how lesions differ from nodules, how they appear on MRI and when they require biopsy.
Evidence Sources
- European Association of Urology — Prostate Cancer Diagnostic Evaluation: DRE performance, PSA limitations, MRI indications, PSA density and biopsy pathways.
- American Urological Association / Society of Urologic Oncology — Early Detection of Prostate Cancer: risk-directed use of PSA, DRE, MRI and biopsy.
- National Cancer Institute — Prostate-Specific Antigen Test: PSA interpretation and benign causes of elevated PSA.
- Differential Diagnosis of Uncommon Prostate Diseases: Combining mpMRI and Clinical Information — review of benign and malignant prostate abnormalities that can overlap with prostate cancer.
- Granulomatous Prostatitis Mimicking Prostate Cancer — clinical and imaging overlap between granulomatous inflammation and malignancy.
- American College of Radiology — PI-RADS: standardized interpretation of suspicious prostate MRI lesions.
